Please use this identifier to cite or link to this item:
Title: A multicenter analysis of the outcome of cancer patients with neutropenia and COVID-19 optionally treated with Granulocyte-Colony Stimulating Factor (G-CSF): A comparative analysis
Filiation: Servicio de Oncología. Hospital Universitario de Fuenlabrada
Issue Date: 20-Aug-2021
Publisher: MDPI AG
Citation: Cancers (Basel).2021 Aug;(13)16:4205
Abstract: Approximately 15% of patients infected by SARS-CoV-2 develop a distress syndrome secondary to a host hyperinflammatory response induced by a cytokine storm. Myelosuppression is associated with a higher risk of infections and mortality. There are data to support methods of management for neutropenia and COVID-19. We present a multicenter experience during the first COVID-19 outbreak in neutropenic cancer patients infected by SARS-CoV-2.
PMID: 34439359
Rights: info:eu-repo/semantics/openAccess
Appears in Collections:Hospitales > H. U. de Fuenlabrada > Artículos
Hospitales > H. U. La Paz > Artículos

Files in This Item:
File Description SizeFormat 
Cancers.pdf1.21 MBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons